english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2010 > The 2010 Prescrire Awards: chosen in all independence by Prescrire's Editorial staff > A look back at new drugs and new indications in 2010 > Prescrire's ratings over 10 years

The Prescrire Awards for 2010

The 2010 Prescrire Awards: chosen in all independence by Prescrire's Editorial staff

A look back at new drugs and new indications in 2010
Prescrire's ratings of new products and indications over the last 10 years

Prescrire's ratings of new products and indications over the last 10 years (a)
PRESCRIRE'S RATING
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
 Bravo 0 0 0 0 0 1 1 0 0 0
 A real advance 2 4 4 0 1 1 2 0 0 1 (c)
 Offers an advantage 11 9 5 6 4 8 14 6 3 (c) 3 (d)
 Possibly helpful 17 18 23 12 20 31 27 25 14 22
 Nothing new
36 35 34 41 38 69 79 57 62 49
 Not acceptable
9 6 (b) 7 (b) 7 19 (d) 17 15 23 19 (d) 19 (e)
 Judgement reserved
7 0 6 4 2 8 3 9 6 (e) 3 (f)
    Total 82 72 79 4 84 135 141 120 104 97
 
Notes :
a - For reasons of space, this table only shows the results for the last 10 years. The previous years’ results (1981 to 2000) can be found in Prescrire Int n°58. This table shows new products (other than generics copies) and new indications proposed by drug companies to physicians and pharmacists, for use in hospitals and/or the community; and, from 2005 onwards, line extensions (new dose strengths, new form/presentations of existing drugs) and products for self-medication, rated in our French edition la revue Prescrire. A given product is counted several times if it was rated differently in its different indications.
b - Including two jointly marketed products.
c - Imatinib reassessed in inoperable or metastatic gastrointestinal stromal tumours (Prescrire Int n°114).
d - The drugs were:
  • azacitidine in some forms of poor-prognosis myelodysplasia (Prescrire Int n°113);
  • canakinumab in periodic syndrome in combination with cryopyrine (Rev Prescrire n°324);
  • Japanese encephalitis vaccine (Prescrire Int n°106).
e - The drugs were:
  • fixed-dose combination of amlodipine + valsartan + hydrochlorothiazide in hypertension (Prescrire Int n°114);
  • bevacizumab in metastatic breast cancer (Rev Prescrire n°317);
  • capsaicin patches for neuropathic pain (Prescrire Int n°108);
  • atumaxomab in malignant ascites (Prescrire Int n° 109);
  • cetuximab in colon cancer (Rev Prescrire n°324);
  • duloxetine in prevention of recurrent depression (Prescrire Int n°111);
  • histamine in acute myeloblastic leukaemia (Rev Prescrire n°321);
  • ivabradine in stable angina (Prescrire Int n°111);
  • long-acting injectable olanzapine in schizophrenia (Prescrire Int n°107);
  • omalizumab in severe persistent asthma in children (Prescrire Int n°115);
  • omalizumab in severe persistent asthma, a reassessment (Prescrire Int n°115);
  • maraviroc in first-line treatment of HIV-infected patients (Prescrire Int n°110);
  • mifamurtide in osteosarcoma (Prescrire Int n°115);
  • pazopanib in kidney cancer (Prescrire Int n°114);
  • sildenafil (Prescrire Int n°109) and tadalafil (Rev Prescrire n°321) in stage II (mild) pulmonary hypertension;
  • temsirolimus in mantle cell lymphoma (Prescrire Int n°111);
  • trabectedin in ovarian cancer (Prescrire Int n°115);
  • vinflunine in bladder cancer after failure of first-line cisplatin-based treatment (Prescrire Int n ° 112).
f - The drugs were:
  • autologous chondrocytes in autologous chondrocyte grafting for knee cartilage damage (Prescrire Int n°116, coming in May 2011);
  • imatinib as an adjuvant to surgical excision of gastrointestinal stromal tumours (Prescrire Int n ° 113);
  • sapropterin in tetrahydrobiopterin deficiency (Prescrire Int n°107).
©Prescrire April 2011
"New drugs and indications in 2010: inadequate assessment; patients at risk" Prescrire Int 2011: 20 (115): 105-110. (Pdf, free)